MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Orthostatic hypotension(OH)"

  • 2019 International Congress

    Predictors of Orthostatic Hypotension in Patients with Parkinson’s Disease

    C-C. Lin, J. Heisler, H. Patel, W. Ondo (Houston, TX, USA)

    Objective: To investigate factors that may affect blood pressure in patients with PD (Parkinson’s disease). Background: PD affects the autonomic nervous system, potentially leading to…
  • 2019 International Congress

    Changes in Supine Blood Pressure with Long Term Use of Droxidopa

    S. Gorny, L. Hewitt, A. Lindsten, M. Karnik-Henry, S. Kymes, A. Favit (Deerfield, IL, USA)

    Objective: To determine the long-term effects of droxidopa use on supine blood pressure (BP) in patients with neurogenic orthostatic hypotension (nOH). Background: nOH is a…
  • 2019 International Congress

    A Phase 2 Study of the Efficacy, Durability and Safety of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

    H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

    Objective: To assess the efficacy and durability using validated symptom questionnaire OHQ, and safety of ampreloxetine, given once-daily to treat neurogenic orthostatic hypotension (nOH) in…
  • 2019 International Congress

    A Phase 2 Dose Escalation Study of Ampreloxetine (TD-9855), a Norepinephrine Reuptake Inhibitor, Given Once-Daily to Treat Neurogenic Orthostatic Hypotension (nOH) in Subjects with Synucleinopathies

    H. Kaufmann, I. Biaggioni, K. Chatamra, A. Panneerselvam, B. Haumann, R. Vickery (New York, NY, USA)

    Objective: To assess the acute effects of ampreloxetine on the pressor response, improvement of symptoms and safety in a daily, single, escalating doses. Background: nOH…
  • 2019 International Congress

    Population Pharmacokinetics and Pharmacodynamics of Ampreloxetine (TD-9855) in Patients with Neurogenic Orthostatic Hypotension (nOH)

    A. Lo, J. Kanodia, R. Vickery, D. Bourdet (South San Francisco, CA, USA)

    Objective: To characterize the Phase 2 pharmacokinetics (PK) and pharmacodynamics (PD) of ampreloxetine in patients with nOH and provide dosing recommendations for special populations in…
  • 2019 International Congress

    Differences in correlation with cardiac sympathetic denervation between depression and anhedonia in drug naïve Parkinson disease patients

    H. Murakami, T. Shiraishi, T. Umehara, S. Omoto, H. Motegi, R. Nakada, T. Sato, A. Onda, H. Matsuno, T. Komatsu, K. Bono, K. Sakai, H. Mitsumura, Y. Iguchi (Tokyo, Japan)

    Objective: To compare the correlation with some assessments of DAT scan and myocardial MIBG scintigraphy between depression and anhedonia in drug naive Parkinson's Disease (PD)…
  • 2019 International Congress

    Entity of excessive daytime sleepiness in Parkinson’s disease

    O. Iakovleva, O. Levin, M. Poluektov (Moscow, Russian Federation)

    Objective: To examine frequency and reasons of excessive daytime sleepiness (EDS) in patients with Parkinson’s disease (PD). Background: Neurodegeneration and dopaminergic medications are known to…
  • 2019 International Congress

    Prevalence and factors related to orthostatic hypotension and orthostatic intolerance in recently-diagnosed, drug-naïve Parkinson’s disease patients

    S. Perez-Lloret, C. Quarracino, F. Capani, M. Otero-Losada (Buenos Aires, Argentina)

    Objective: To explore the prevalence and factors related to orthostatic hypotension (OH) and orthostatic intolerance (OI) in recently diagnosed drug-naïve PD patients from the Parkinson’s…
  • 2019 International Congress

    Alterations of Blood Pressure Circadian Rhythm in Alpha-Synucleinopathies

    A. Romagnolo, F. Vallelonga, A. Merola, C. Di Stefano, G. Sobrero, V. Milazzo, M. Zibetti, CA. Artusi, M. Fabbri, MG. Rizzone, S. Maule, L. Lopiano (Turin, Italy)

    Objective: To analyze the blood pressure (BP) circadian rhythm in Parkinson’s disease (PD), multiple system atrophy (MSA), and pure autonomic failure (PAF), evaluating possible differences…
  • 2019 International Congress

    The prevalence of supine hypertension and nocturnal hypertension and the difference of blood pressure in each sleep position in Parkinson’s disease

    J. Sringean, R. Hamindra, R. Bhidayasiri (Bangkok, Thailand)

    Objective: This study aimed to determine the prevalence, associated factors of SH/NH and to identify relationships between blood pressure (BP) and sleep position in PD…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley